Isis Pharmaceuticals CEO Unloads $1,239,525 in Stock (ISIS)
Isis Pharmaceuticals (NASDAQ:ISIS) CEO Stanley Crooke sold 31,500 shares of Isis Pharmaceuticals stock on the open market in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $39.35, for a total transaction of $1,239,525.00. Following the sale, the chief executive officer now directly owns 1,661 shares of the company’s stock, valued at approximately $65,360. The sale was disclosed in a document filed with the SEC, which is available at this link.
Isis Pharmaceuticals (NASDAQ:ISIS) traded down 2.23% during mid-day trading on Friday, hitting $38.98. The stock had a trading volume of 784,371 shares. Isis Pharmaceuticals has a 1-year low of $10.48 and a 1-year high of $42.69. The stock has a 50-day moving average of $37.79 and a 200-day moving average of $32.34. The company’s market cap is $4.525 billion.
Isis Pharmaceuticals (NASDAQ:ISIS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.06. The company had revenue of $23.60 million for the quarter, compared to the consensus estimate of $19.82 million. During the same quarter in the previous year, the company posted ($0.37) earnings per share. The company’s revenue for the quarter was up 103.4% on a year-over-year basis.
Several analysts have recently commented on the stock. Analysts at Piper Jaffray upgraded shares of Isis Pharmaceuticals from an “underweight” rating to a “neutral” rating in a research note to investors on Tuesday, November 26th. They now have a $38.00 price target on the stock, up previously from $25.00. Analysts at Zacks reiterated a “neutral” rating on shares of Isis Pharmaceuticals in a research note to investors on Thursday, November 7th. They now have a $33.00 price target on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $36.18.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.